## Nancy M Heddle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7023382/publications.pdf

Version: 2024-02-01

87888 71685 6,217 135 38 76 citations g-index h-index papers 143 143 143 4857 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prolonged Blood Storage and Risk of Posttransfusion Acute Kidney Injury. Anesthesiology, 2022, 136, 138-147.	2.5	1
2	From demand forecasting to inventory ordering decisions for red blood cells through integrating machine learning, statistical modeling, and inventory optimization. Transfusion, 2022, 62, 87-99.	1.6	10
3	Use of Irradiated Red Blood Cell Transfusions in Newborns to Improve Intracerebral Saturation. JAMA Pediatrics, 2022, , e220149.	6.2	О
4	Databaseâ€driven research and big data analytic approaches in transfusion medicine. Transfusion, 2022, 62, 1427-1434.	1.6	3
5	Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy. Transfusion, 2021, 61, 286-293.	1.6	6
6	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials, 2021, 22, 323.	1.6	21
7	A decision integration strategy for short-term demand forecasting and ordering for red blood cell components. Operations Research for Health Care, 2021, 29, 100290.	1.2	22
8	Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia. Blood Advances, 2021, 5, 4256-4264.	5.2	4
9	Necrotizing enterocolitis and mortality after transfusion of ABO nonâ€identical blood. Transfusion, 2021, 61, 3094-3103.	1.6	3
10	Cost-effectiveness of eltrombopag versus intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. Blood Advances, $2021,\ldots$	5.2	7
11	Devices to Reduce the Volume of Blood Taken for Laboratory Testing in ICU Patients: A Systematic Review. Journal of Intensive Care Medicine, 2020, 35, 1074-1079.	2.8	17
12	Blood loss from laboratory testing, anemia, and red blood cell transfusion in the intensive care unit: a retrospective study. Transfusion, 2020, 60, 256-261.	1.6	23
13	Platelet transfusion practice and platelet refractoriness for a cohort of pediatric oncology patients: A singleâ€center study. Pediatric Blood and Cancer, 2020, 67, e28734.	1.5	3
14	Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. Lancet Haematology,the, 2020, 7, e640-e648.	4.6	16
15	Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion. Transfusion, 2020, 60, 1604-1611.	1.6	5
16	Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to riskâ€stratify patients for alloimmunisation risk. Transfusion Medicine, 2020, 30, 263-274.	1.1	3
17	A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets. Transfusion, 2020, 60, 1267-1277.	1.6	10
18	Genome-Wide Association Study Identifies Variation in <i>ABO</i> As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia. Blood, 2020, 136, 38-39.	1.4	1

#	Article	IF	Citations
19	Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery. JAMA - Journal of the American Medical Association, 2019, 322, 1966.	7.4	106
20	Not all red cell concentrate units are equivalent: international survey of processing and in vitro quality data. Vox Sanguinis, 2019, 114, 783-794.	1.5	14
21	Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The) Tj ETQq $1\ 1$	0.784314 3.4	rgBT /Overlo
22	Sexâ€mismatched red blood cell transfusions and mortality: A systematic review and metaâ€analysis. Vox Sanguinis, 2019, 114, 505-516.	1.5	31
23	The association between platelet transfusions and mortality in patients with critical illness. Transfusion, 2019, 59, 1962-1970.	1.6	11
24	The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. Transfusion, 2019, 59, 482-491.	1.6	51
25	Impact of organizational interventions on reducing inappropriate intravenous immunoglobulin (IVIG) usage: A systematic review and meta-analysis. Transfusion and Apheresis Science, 2018, 57, 215-221.	1.0	7
26	Critical developments of 2017: a review of the literature from selected topics in transfusion. A committee report from the AABB Clinical Transfusion Medicine Committee. Transfusion, 2018, 58, 1065-1075.	1.6	2
27	An international investigation into AB plasma administration in hospitals: how many AB plasma units were infused? The HABSWIN study. Transfusion, 2018, 58, 151-157.	1.6	4
28	Exploring donor and product factors and their impact on red cell post-transfusion outcomes. Transfusion Medicine Reviews, 2018, 32, 28-35.	2.0	39
29	Clinical Outcomes and Red Blood Cell Storage. , 2018, , 305-319.		O
30	Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion, 2018, 58, 2729-2735.	1.6	37
31	Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion, 2018, 58, 2841-2860.	1.6	12
32	Top 10 mistakes made in research. Transfusion, 2018, 58, 2478-2482.	1.6	1
33	Neutropenia and monocytopenia in recurrent anaphylactoid reactions after red blood cell transfusions in a woman with immunoglobulin A (lgA) deficiency and antiâ€lgA. Transfusion, 2018, 58, 2320-2325.	1.6	2
34	Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood, 2018, 132, 223-231.	1.4	71
35	Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial. BMJ Open, 2018, 8, e020741.	1.9	15
36	Short-Term versus Long-Term Blood Storage. New England Journal of Medicine, 2017, 376, 1091-1094.	27.0	5

#	Article	IF	Citations
37	Warmâ€reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: review of the literature and survey of current practice. Transfusion, 2017, 57, 463-477.	1.6	25
38	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. Lancet Haematology,the, 2017, 4, e544-e552.	4.6	34
39	From cytokines to pragmatic designs: changing paradigms. Transfusion, 2017, 57, 2298-2306.	1.6	1
40	Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients. Transfusion, 2017, 57, 137-143.	1.6	15
41	Quantification of Cell-Free DNA in Red Blood Cell Units in Different Whole Blood Processing Methods. Journal of Blood Transfusion, 2016, 2016, 1-5.	3.3	14
42	Transfusion premedication practices among pediatric health care practitioners in Canada: results of a national survey. Transfusion, 2016, 56, 2296-2302.	1.6	11
43	CONSORT and clinical trial reporting: room for improvement. Transfusion, 2016, 56, 781-783.	1.6	3
44	A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open, 2016, 6, e010156.	1.9	22
45	Platelet Transfusion Practices in the ICU. Chest, 2016, 150, 516-523.	0.8	37
46	Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood, 2016, 127, 400-410.	1.4	94
47	Clinical Practice Guidelines From the AABB. JAMA - Journal of the American Medical Association, 2016, 316, 2025.	7.4	871
48	Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. Transfusion, 2016, 56, 73-79.	1.6	8
49	Red blood cell transfusion: 2016 clinical practice guidelines from AABB. Transfusion, 2016, 56, 2627-2630.	1.6	36
50	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. New England Journal of Medicine, 2016, 375, 1937-1945.	27.0	278
51	An evaluation of overall effectiveness and treatment satisfaction with intravenous immunoglobulin among patients with immune thrombocytopenia. Transfusion, 2016, 56, 1739-1744.	1.6	6
52	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. Transfusion Medicine Reviews, 2016, 30, 25-29.	2.0	15
53	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. Lancet Haematology,the, 2016, 3, e246-e254.	4.6	57
54	Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood, 2015, 126, 597-603.	1.4	101

#	Article	IF	Citations
55	Exploratory studies on the age of transfused blood and inâ€hospital mortality in patients with cardiovascular diagnoses. Transfusion, 2015, 55, 364-372.	1.6	25
56	A benchmarking program to reduce red blood cell outdating: implementation, evaluation, and a conceptual framework. Transfusion, 2015, 55, 1621-1627.	1.6	5
57	Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematology,the, 2015, 2, e75-e81.	4.6	99
58	Intravenous Immunoglobulin (IVIg) Utilization in Immune Thrombocytopenia (ITP): A Multi-Center, Retrospective Review. Drugs - Real World Outcomes, 2015, 2, 35-42.	1.6	11
59	Perioperative Management of Dabigatran. Circulation, 2015, 132, 167-173.	1.6	133
60	A 13-Question Approach to Resolving Serological Discrepancies in the Transfusion Medicine Laboratory. Laboratory Medicine, 2014, 45, 193-206.	1.2	14
61	Prophylactic platelet transfusions. Current Opinion in Hematology, 2014, 21, 521-527.	2.5	4
62	Risks, benefits and the role of stakeholders in pathogen reduction technology. Health, Risk and Society, 2014, 16, 547-564.	1.7	3
63	A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. Transfusion, 2013, 53, 1328-1334.	1.6	5
64	Exploring resource allocation and alternate clinic accessibility landscapes for improved blood donor turnout. Applied Geography, 2013, 45, 89-97.	3.7	11
65	The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion, 2013, 53, 1531-1543.	1.6	46
66	Clinical trials evaluating pathogenâ€reduced platelet products: methodologic issues and recommendations. Transfusion, 2013, 53, 1843-1855.	1.6	14
67	Transfusion-Related Iron Overload: A Covert Risk Of Supportive Cancer Care. Blood, 2013, 122, 3656-3656.	1.4	1
68	Transfusion Related Alloimmunization In Children: Epidemiology and Effects Of Chemotherapy (TRACE-EC Study). Blood, 2013, 122, 1161-1161.	1.4	0
69	Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. Blood, 2013, 122, 3651-3651.	1.4	6
70	Perioperative Management Of Patients On Dabigatran – a Prospective Cohort Study. Blood, 2013, 122, 3637-3637.	1.4	0
71	The Use Of Platelet Transfusions In The Intensive Care Unit and Impact On Platelet Count: A 30,000 Patient Registry Study. Blood, 2013, 122, 1154-1154.	1.4	0
72	A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood, 2012, 119, 1356-1362.	1.4	111

#	Article	IF	Citations
73	Benchmarking: Applications to Transfusion Medicine. Transfusion Medicine Reviews, 2012, 26, 321-332.	2.0	15
74	Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. The Cochrane Library, 2012, , CD004269.	2.8	66
75	Forecasting Ontario's blood supply and demand. Transfusion, 2012, 52, 366-374.	1.6	74
76	Individual and contextual determinants of blood donation frequency with a focus on clinic accessibility: A case study of Toronto, Canada. Health and Place, 2012, 18, 424-433.	3.3	27
77	Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). Transfusion, 2012, 52, 1687-1695.	1.6	27
78	The effect of blood storage duration on inâ€hospital mortality: a randomized controlled pilot feasibility trial. Transfusion, 2012, 52, 1203-1212.	1.6	61
79	A new tool to assess bleeding severity in patients with chemotherapyâ€induced thrombocytopenia (CME). Transfusion, 2012, 52, 2466-2474.	1.6	31
80	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion, 2012, 52, 1363-1378.	1.6	11
81	Use of Intravenous Immune Globulin in Patients with Immune Thrombocytopenia Before and After Romiplostim: Real-World Experience. Blood, 2012, 120, 4641-4641.	1.4	0
82	Are Children with Cancer Receiving Myelosuppressive Therapy At Risk for Transfusion-Related Iron Overload?. Blood, 2012, 120, 1180-1180.	1.4	0
83	Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. Blood, 2012, 120, 1186-1186.	1.4	0
84	Composite outcomes in clinical trials: what are they and when should they be used?. Transfusion, 2011, 51, 11-13.	1.6	17
85	Time to rethink clinically important outcomes in platelet transfusion trials. Transfusion, 2011, 51, 430-434.	1.6	36
86	Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges. Transfusion, 2011, 51, 2304-2310.	1.6	25
87	Do expert assessments converge? An exploratory case study of evaluating and managing a blood supply risk. BMC Public Health, 2011, 11, 666.	2.9	6
88	Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood, 2010, 115, 29-31.	1.4	65
89	The randomized controlled trial: in celebration of TRANSFUSION's 50th. Transfusion, 2010, 50, 1173-1178.	1.6	0
90	A systematic assessment of the quality of reporting for platelet transfusion studies. Transfusion, 2010, 50, 2135-2144.	1.6	19

#	Article	IF	Citations
91	Duration of red cell storage before transfusion and in-hospital mortality. American Heart Journal, 2010, 159, 737-743.e1.	2.7	101
92	Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study. Blood, 2010, 116, 392-392.	1.4	0
93	Geographical variations in the correlates of blood donor turnout rates: An investigation of Canadian metropolitan areas. International Journal of Health Geographics, 2009, 8, 56.	2.5	31
94	Factors affecting the frequency of red blood cell outdates: an approach to establish benchmarking targets. Transfusion, 2009, 49, 219-226.	1.6	30
95	CONSORT comes to TRANSFUSION. Transfusion, 2009, 49, 194-195.	1.6	4
96	Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies. Transfusion, 2009, 49, 2276-2284.	1.6	23
97	Reviewing manuscripts: tips and responsibilities. Transfusion, 2009, 49, 2265-2268.	1.6	8
98	A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood, 2009, 113, 1564-1573.	1.4	150
99	Platelet quality measured with dynamic light scattering correlates with transfusion outcome in hematologic malignancies. Transfusion, 2009, , no-no.	1.6	0
100	Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review. Transfusion, 2008, 48, 1447-1458.	1.6	71
101	Errors in patient specimen collection: application of statistical process control. Transfusion, 2008, 48, 2143-2151.	1.6	30
102	A policy informing qualitative study to improve the process of blood product recalls and withdrawals. Transfusion, 2008, 48, 2585-2595.	1.6	6
103	New Strategies for the Optimal Use of Platelet Transfusions. Hematology American Society of Hematology Education Program, 2008, 2008, 198-204.	2.5	82
104	Febrile, Allergic, and Other Noninfectious Transfusion Reactions., 2007,, 677-690.		1
105	The research question. Transfusion, 2007, 47, 15-17.	1.6	33
106	Clinical research design and reporting: always room for improvement!. Transfusion, 2007, 47, 2-3.	1.6	8
107	Prevention of bedside errors in transfusion medicine (PROBE-TM) study: a cluster-randomized, matched-paired clinical areas trial of a simple intervention to reduce errors in the pretransfusion bedside check. Transfusion, 2007, 47, 771-780.	1.6	39
108	A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion, 2007, 48, 071003012013009-???.	1.6	53

#	Article	IF	Citations
109	Designing laboratory-based research studies: is it time for a change?. Transfusion, 2007, 47, 2336-2337.	1.6	1
110	Design issues with clinical experimental platelet transfusion studies. Transfusion Alternatives in Transfusion Medicine, 2006, 8, 106-113.	0.2	1
111	The premature infants in need of transfusion (pint) study: A randomized, controlled trial of a restrictive (LOW) versus liberal (HIGH) transfusion threshold for extremely low birth weight infants. Journal of Pediatrics, 2006, 149, 301-307.e3.	1.8	497
112	In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion, 2006, 46, 257-264.	1.6	40
113	A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion, 2006, 46, 903-911.	1.6	45
114	Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion, 2006, 46, 1286-1291.	1.6	65
115	A study of the agreement between patient self-assessment and study personnel assessment of bleeding symptoms. Transfusion, 2006, 46, 1926-1933.	1.6	7
116	The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica, 2006, 91, 1530-7.	3.5	110
117	Pitfalls in Interpreting Platelet Function Tests in Thrombocytopenic Patients Referred by a Hematologist for Diagnostic Testing: Results from a Single Center Prospective Study Blood, 2005, 106, 3982-3982.	1.4	0
118	Universal leukoreduction and acute transfusion reactions: putting the puzzle together. Transfusion, 2004, 44, 1-4.	1.6	23
119	Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation., 2004,, CD004269.		53
120	Triple Immunosuppressive Therapy in Patients with Chronic Resistant Immune Thrombocytopenic Purpura; a Case Series of 11 Patients Blood, 2004, 104, 2059-2059.	1.4	1
121	Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion, 2003, 43, 742-752.	1.6	85
122	Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. Transfusion, 2002, 42, 753-758.	1.6	41
123	A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion, 2002, 42, 556-566.	1.6	189
124	Evidenceâ€based clinical reporting: a need for improvement. Transfusion, 2002, 42, 1106-1110.	1.6	5
125	Clinical Research Designs: Quantitative Studies. Vox Sanguinis, 2002, 83, 247-250.	1.5	3
126	A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion, 1999, 39, 231-238.	1.6	139

#	Article	IF	Citations
127	Pathophysiology of febrile nonhemolytic transfusion reactions. Current Opinion in Hematology, 1999, 6, 420.	2.5	118
128	Febrile nonhemolytic transfusion reactions to platelets. Current Opinion in Hematology, 1995, 2, 478-483.	2.5	40
129	A prospective study to determine the frequency and clinical significance of alloimmunization postâ€transfusion. British Journal of Haematology, 1995, 91, 1000-1005.	2.5	159
130	The use of antiâ€D to improve postâ€transfusion platelet response: a randomized trial. British Journal of Haematology, 1995, 89, 163-168.	2.5	11
131	The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. British Journal of Haematology, 1994, 86, 347-350.	2.5	107
132	The Role of the Plasma from Platelet Concentrates in Transfusion Reactions. New England Journal of Medicine, 1994, 331, 625-628.	27.0	504
133	A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing. British Journal of Haematology, 1992, 81, 579-584.	2.5	42
134	Acute Paroxysmal Cold Hemoglobinuria. Transfusion Medicine Reviews, 1989, 3, 219-229.	2.0	82
135	Febrile and Allergic Transfusion Reactions. , 0, , 83-89.		1